Context: Ulipristal acetate (UPA), a selective progesterone receptor modulator, clinically reduces uterine myoma size in 80% of cases. However, the molecular mechanism of action is still poorly understood, as is the reason why 20% of myomas do not respond to treatment.
synthesis of the extracellular matrix (ECM), resulting in abundant and disorganized collagen deposits (3, 4) . Whereas myoma cells actually proliferate at a modest rate, the ECM fraction often represents .50% of their volume (5, 6) . The rigid environment generated by excessive collagen, fibronectin, and proteoglycan deposits can cause altered mechanical stress, promoting cell proliferation and tumorigenesis (7) . However, the origin of this ECM overabundance is still unclear, and the etiology of myomas remains a matter of debate. Whereas genetic alterations in myoma stem cells may play a role in disease initiation, sex steroid hormones appear to promote cell proliferation and ECM synthesis in uterine myomas (8) .
Myomas are known to overexpress progesterone receptors (PRs), and the central role of progesterone in this pathology (9, 10) has led to clinical application of selective PR modulators, such as ulipristal acetate (UPA) (2) . Myomas typically show a marked reduction in size, from 35% after a single 3-month course of treatment with UPA 5 mg/day (11, 12) to 50% after repeated courses of treatment (13, 14) , before eventually disappearing completely (2, 15) . In 25% of cases, however, myomas do not respond to treatment, and no shrinkage is observed (16) .
Myoma volume reduction induced by UPA treatment is multifactorial; indeed, UPA (1) modestly inhibits proliferation, (2) induces a temporary phase of apoptosis, and (3) reduces ECM content, particularly after longterm (LT) therapy (6) . In vitro, UPA decreases ECM synthesis (17, 18) and increases expression of a wide range of matrix metalloproteinases (MMPs) in cultured myoma cells (17) . We previously postulated that stimulation of MMP-2 expression in UPA-treated tissues could be responsible for reducing ECM content (6), but questions as to how UPA mediates its multifactorial effects, and why some myomas do not shrink at all remain unanswered. The aim of the current study was to investigate whether differences in MMP and tissue inhibitor of metalloproteinase (TIMP) expression and activity could explain the response or lack of response of uterine myomas to UPA therapy.
Materials and Methods

Patients
Fifty-nine patients with symptomatic myomas, but free of any hormone therapy for at least 3 months before enrollment, were selected for this study. Forty-five patients were given daily preoperative treatment with either one, 3-month course UPA [short-term (ST)] or two to four, 3-month courses (LT) in the context of clinical studies (13, 14) . Myomas were individually monitored by magnetic resonance imaging in the course of their clinical management. Their volume was calculated using the formula 4 3 p x 2 y 2 z 2 in mm 3 (where x, y, and z represent the maximum length of each coordinate) and expressed in fold change compared with pretreatment volume. Response to UPA was considered important when at least a 25% reduction in volume was obtained, whereas a lack of response was recorded when myoma volume did not change or increased during treatment (11) (12) (13) . Patients were further classified as either "responsive" (R), forming two groups (ST-R, n = 12; LT-R, n = 14), or "nonresponsive" [(NR) group, n = 19]. The control group included 14 women with symptomatic myomas who were not given any hormone therapy in the 3 months leading up to surgery (further referred to as "untreated"). All patients underwent myomectomy or hysterectomy and gave their informed consent to participate in the study. The benign status of myomas was confirmed by an experienced pathologist (E.M.). Use of human tissue for this study was approved by the Institutional Review Board of the Université Catholique de Louvain, Brussels, Belgium (IRB 2015/19OCT/556).
Tissue samples
Immediately after surgery, fresh myoma biopsies were dissected into 2 mm 3 pieces on ice, snap frozen, and kept at 280°C. Larger fragments were fixed in 4% formaldehyde in buffered saline solution (VWR, Leuven, Belgium) and embedded in paraffin for immunohistochemistry (IHC).
Gel zymography and reverse zymography
MMP-1, MMP-3, and MMP-7 were assayed by casein zymography and MMP-2 and MMP-9 by gelatin zymography, as previously described (19) . In brief, 10 mg snap-frozen tissue was dissociated with tissue homogenizer (Janke and Kunkel, Staufen, Germany) in 1.0 ml 50 mM Tris-HCl (pH 7.5), 10 mM CaCl 2 , 0.15 M NaCl, 1 mM ZnCl 2 , 0.2 mg/ml NaN 3 , and 0.1% Triton X-100. DNA concentrations were quantified using 4 0 ,6-diamidino-2-phenylindole to normalize loading, as detailed in an earlier publication (20) , and a volume equivalent to 100 ng DNA was deposited per well. Zymography was performed on acrylamide gels with copolymerized substrate (8% acrylamide with 0.5 mg/ml gelatin or 12% acrylamide with 0.5 mg/ml casein). After sodium dodecyl sulfate removal by successive Triton X-100 washes, the gels were incubated for 16 hours at 37°C in 50 mmol/L Tris-HCl (pH 7.5), 5 mmol/L CaCl 2 , 0.2 mg/mL NaN 3 , 1% (v/v) Triton X-100, and 1 mmol/L ZnCl 2 to allow enzymatic activity. Concentrated conditioned media from endometrial explants served as standard and common references between the gels (20) . The inhibitory functions of TIMP-1 and TIMP-2 were evaluated by reverse zymography using 15% polyacrylamide and 0.5 mg/ml gelatin gels. Incubation was performed with shaking for 24 hours at 37°C in the same buffer as for zymography but supplemented with concentrated MMP-rich conditioned medium treated with 2 M 4-aminophenylmercuric acetate for 2 hours at 25°C before incubation (20) . The equivalent of 400 ng DNA was loaded per well. Five microliters of prestained 10 to 250 kDa protein ladder (Thermo Fisher Scientific, Ghent, Belgium) was used as a common reference between the gels and the 15-kDa band intensity for quantification normalization. Experiments were conducted, at least in duplicate, on independent gels. Densitometric quantification of signal intensity was achieved using the gel plot line tool on ImageJ (v1.51j; National Institutes of Health, Bethesda, MD).
IHC and staining quantification
IHC was performed as previously reported (6). References and parameters of primary antibodies for (pro)MMP-1, (pro)MMP-2, and (pro)MMP-3 (and -10) and TIMP-1 and -2 are listed in Supplemental Table 1 . Human endometrium in the menstrual phase of the cycle, placenta, and pancreatic tissue served as positive tissue controls (Biolibrary of the Université Catholique de Louvain; Supplemental Fig. 1 ). Comprehensive images of the slides were obtained with the Leica SCN400 slide scanner at 203 magnification. Computer-assisted quantification of staining concentrations in tissue was carried out with Leica proprietary artificial intelligence (TissueIA, Wetzlar, Germany), as detailed elsewhere (21) 
Statistical analyses
Descriptive analysis of values (D'Agostino and Pearson or Shapiro-Wilk normality tests) was conducted before the statistical parametric analysis of variance test or when required, the nonparametric two-tailed Kruskal-Wallis test, followed, respectively, by Holm-Sidak or Dunn multiple comparisons test. Correlations between IHC or zymography results and myoma volume fold change were established using a linear regression model, and Spearman coefficients were then calculated. P = 0.05 was considered statistically significant. All tests were done using Prism 7.0 software (GraphPad, La Jolla, CA).
Results
Gel zymography and reverse zymography
The proteolytic activity of MMP-1, MMP-3, MMP-7, and MMP-10 in tissue lysates was assessed on casein zymograms (Fig. 1A) . Untreated myomas were found to express a proteolytic activity, possibly corresponding to latent and active MMP-1, MMP-3, or MMP-10. Compared with untreated patients, UPA-R myomas showed a significant increase in total (combined latent and active forms) MMP-1, -3, or -10 expression and activity (P , 0.0001), whereas NR samples did not ( Fig. 2A) . MMP-7 was not detected in any myoma samples.
The gelatinolytic activity of MMP-2 and MMP-9 was investigated by gelatin zymography (Fig. 1B) . Total MMP-2 levels were significantly higher in UPA-R myomas than in untreated or NR samples (P = 0.009 and P = 0.013, respectively; Fig. 2A ). MMP-9 bands were never detected in untreated or NR samples and only very rarely in UPA-R myomas (as illustrated for ST-R; Fig. 1B) .
With the use of a linear regression model, MMP-1, -3, or -10 and MMP-2 expression levels were compared with ascertain myoma volume fold change after UPA treatment. A significant correlation was found between high MMP activity and myoma volume reduction (MMP-1, -3, or -10: r = 20.701, r 2 = 0. 578, P , 0.0001; MMP-2: r = 20.622, r 2 = 0.387, P , 0.0001; Fig. 2A ).
The inhibitory action of TIMPs was tested by reverse zymography. TIMP-1 and TIMP-2 were detected at their respective sizes (28 and 21 kDa) in all groups (Fig. 1C) . Quantitative analysis evidenced lower TIMP-1 band intensity in R samples than in controls (P = 0.040; Fig. 2C ). No significant change in TIMP-2 expression was observed between groups.
IHC
To characterize further the respective expression and distribution of MMP-1, -2, -3, and -10 and TIMP-1 and -2, these proteins were labeled on tissue sections by IHC using monoclonal antibodies (Fig. 3) . For MMPs, antibodies that react with both precursor and active forms were chosen.
The antibody against (pro)MMP-1 provided a signal inside myoma cells and the ECM, which was found to be stronger in 90% (n = 19/21, as five samples were not suitable for this analysis) of R myomas compared with NR myomas. Quantification, based on the intensity and extent of the signal, revealed significantly higher MMP-1 levels in the UPA-R group (ST-R and LT-R groups combined) than in NR myomas (P = 0.010; Fig. 2B) .
No staining for MMP-3 and -10 was detected in the studied myoma samples, suggesting that the bands identified by casein zymography were actually a reflection of MMP-1 activity (22) .
Intracellular and extracellular signals corresponding to precursor and mature MMP-2 forms, respectively, were detected in all myoma groups, with the R groups showing a marked increase in signal distribution and intensity. Quantification of MMP-2 staining confirmed higher concentrations in UPA-R myomas than in untreated (P = 0.013) or NR (P = 0.002) myomas (Fig. 2B ).
This increase was most pronounced in the LT-R group vs NR myomas (P = 0.007).
As with zymography, a significant correlation was found between abundant and intense MMP-1 or -2 staining and decreased myoma volume (MMP-1: r = 20.419, r 2 = 0.176, P = 0.017; MMP-2: r = 20.515, r 2 = 0.265, P = 0.010; Fig. 2B ).
TIMP-1 and -2 showed faint and diffuse labeling in myoma samples, although the signal was saturated in tissue controls (Supplemental Fig. 1 ). Staining quantification identified a slight decrease in signal intensity for TIMP-1, which partially reproduced the pattern observed by reverse zymography, but there, the difference was not significant (Fig. 2D) . 
Discussion
Substantial ($25%) and sustained regression of most myomas is typically observed in 75% to 80% of patients after UPA treatment (2). In some cases, there is complete disappearance of the myoma (15), indicating complete resorption of its cellular and extracellular components. We previously reported that UPA treatment triggers multifactorial mechanisms in uterine myomas through a combination of proliferation inhibition, temporary induction of apoptosis, and a reduction in the ECM volume fraction, presumed to be a result of concomitant stimulation of MMP-2 protein expression (6) . Based on these results, we felt it was essential to characterize further ECM remodeling by analyzing MMP and TIMP expression in terms of clinical reduction of uterine myomas after UPA treatment.
Regulatory mechanisms of MMP expression and activity MMP expression and activity are tightly regulated by complex mechanisms. At the gene level, progesterone represses MMP expression (19) . Although MMP genes lack progesterone response elements in their promoter regions, progesterone mediates its repressive action by interfering with nuclear transcription factors that bind to MMP promoter sequences, such as nuclear factor-kB and activator protein 1 (23) . Besides gene regulation, MMP expression and activity are dynamically controlled by the following: (1) mRNA stability regulation, (2) posttranslational modifications altering protein stability or activity, (3) enzymatic activation by self-cleavage or by other MMPs, (4) formation of MMP complexes, (5) the relative abundance of their inhibitors (tissue or serum inhibitors) (23), or (6) even means of recapture and degradation by cells (24) . Moreover, local ECM proteolysis can lead to loss of stiffness, which reduces intracellular tension and promotes MMP expression via activator protein 1 in a positive feedback loop toward further ECM remodeling (25) . All of these regulations may depend on the local environment and be tissue specific, adding another level of complexity to the governing mechanisms.
In vivo, myoma tissue samples from untreated or UPA-treated patients (Rs and NRs) did not exhibit any substantial difference when compared with IHC for expression and localization of PR, its two main isoforms (PR-A and PR-B), and their nuclear cofactors, B cell lymphoma 2 (for genomic signaling) and phosphorylated Akt/Akt (for nongenomic signaling) (26) . Differential regulation of MMP activity, according to response, might therefore depend on PR-independent mechanisms.
MMP and TIMP expression and activity in uterine myomas
Clinical practice indicates that UPA antagonizes progesterone action in uterine myomas, suggesting possible induction of MMP expression. In the current study, two complementary approaches demonstrated that MMP-1 and -2 and TIMP-1 and -2 were expressed in uterine myomas, with a marked increase in MMP expression and a slight decrease in TIMP levels in R myomas but not in NR myomas. Therefore, these results support the notion that UPA does indeed counteract progesterone and trigger MMP expression. In vitro studies on isolated myoma cells treated with UPA or asoprisnil (another selective PR modulator closely related to UPA) have revealed direct stimulation of MMP-1 and -2 transcription in a dose-dependent manner (17, 27) . Xu et al. (17) also identified the key role of the MMP inducer ECM metalloproteinase inducer in MMP stimulation, observed in myoma cells after UPA exposure. However, we were not able to detect any substantial difference in ECM metalloproteinase inducer expression among controls, Rs, and NRs (data not shown), suggesting that differential MMP activity, according to response, depends on other mechanisms, probably at the post-translational level.
This in vivo study correlates MMP expression and activity levels with UPA response. In women, uterine myomas show variable MMP levels during different phases of the menstrual cycle, indicating hormonal control (28) . Furthermore, suppression of progesterone upregulates MMP-1, -2, and -3 mRNA and protein levels but reduces TIMP-1 expression in myomas (28) . The modest repression of TIMPs observed in UPA-R patients is consistent with the fact that in vivo, control of TIMP expression by progesterone is not as strong as control of MMPs (29) . Nevertheless, although slight, the decrease in TIMP-1 levels observed in UPA-R groups, combined with higher MMP-1 and -2 levels, results in a MMP/TIMP balance superior to that found in untreated or NR myomas. Therefore, our results support the hypothesis that UPA induces MMP activity in situ and hence, enhances ECM resorption.
Biological relevance of MMP expression and activity
The fibrotic nature of uterine myomas is a major feature of the disease (30) : the ECM volume fraction represents ;50% of their total volume (6, 31, 32) . This fibrosis is the result of dysregulation of collagen deposition and organization, particularly that of fibrillar type I and III and nonfibrillar type IV collagens, during the proliferative and secretary phases (4). Collagenassociated proteins (such as fibronectin, tenascin, and laminin), proteoglycans (versican, biglycan, and decorin), and glycosaminoglycans constitute the remaining part of the ECM of uterine myomas (7, (33) (34) (35) , which is regulated by dynamic hormonal and physicochemical signaling. As far as hormones are concerned, progesterone contributes to transforming growth factor b (TGFb)-mediated stimulation of collagen and proteoglycan expression. Interestingly, accumulating evidence indicates that UPA impairs TGF-b signaling (36) , so it would be reasonable to assume that UPA represses collagen synthesis, as observed in vitro (17), by counteracting TGF-b signaling. In vivo, although UPA induces a considerable decrease in ECM volume, it was never associated with any substantial change in collagen synthesis (6, 18) . The substantial reduction in myoma volume, observed in Rs, therefore points to ECM degradation. Importantly, collagen types, their distribution in the ECM, and their degree of crosslinking could vary between myomas and may mediate resistance to MMPs (37) . Thus, it can be speculated that either (1) NR myomas contain higher crosslinking enzymes than responders, or (2) UPA represses these enzymes more efficiently in R myomas, facilitating ECM resorption by MMPs.
On the other hand, UPA decreases synthesis of hydrophilic proteoglycans (18) , but exactly how this action contributes to myoma volume reduction has yet to be determined. Mitigating water retention and osmotic stress in myomas (36) could give rise to MMP synthesis in a positive feedback loop toward further ECM remodeling. On this basis, the intrinsic nature of the ECM of each myoma could predispose it to its inherent response to UPA.
Taken together, the present results cannot exclude the possibility that the response to UPA also involves effects on ECM synthesis, but our data clearly show that UPA has a decisive impact on ECM remodeling by tilting the MMP/TIMP balance toward degradation.
Finally, whereas MMP-1 and MMP-2 differ in their specificity toward substrates, their cumulative action should be sufficient to hydrolyze most of these substrates (38, 39) . Indeed, injection of purified collagenase into uterine myomas resulted in efficient softening of the tissue in only 24 hours and almost total resorption of the ECM (31, 32) . Therefore, MMPs are biologically relevant in the context of uterine myomas, capable of inducing a volume reduction up to 50%, which could explain their longlasting benefits (6) .
Conclusion
In this study, we have shown that reduction of myoma volume after UPA treatment correlates with an increase in MMP-1 and MMP-2 activity. This increase can be explained by the positive MMP/TIMP balance achieved, thanks to much higher MMP-1 and -2 protein levels, accompanied by a modest reduction in TIMP expression. In conclusion, our data further support the hypothesis that MMPs are central players in UPA-mediated volume reduction of uterine myomas and provide a differential indicator between myomas that respond or not to UPA treatment. 
